Skip to main content
SpringerLink
Log in

Spotlight on Ranolazine in Chronic Stable Angina Pectoris

  • Adis Spotlight
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Ranolazine (Ranexa™), a piperazine derivative, is a new antianginal agent approved for the treatment of chronic stable angina pectoris for use as combination therapy when angina is not adequately controlled with other antianginal agents. While the exact mechanism of action of ranolazine is not known, its antianginal and anti-ischemic effects do not appear to depend upon changes in BP or heart rate. An extended-release (ER) oral formulation of ranolazine has been developed to facilitate twice-daily administration whilst maintaining therapeutically effective plasma concentrations.

In patients with chronic stable angina, ranolazine ER monotherapy was shown to improve exercise duration at trough plasma drug concentration in a dose-dependent manner compared with placebo. The drug was effective as adjunctive therapy in patients with chronic stable angina whose condition was not controlled adequately with conventional antianginal therapy. In randomized clinical trials, ranolazine ER was well tolerated, with no overt effects on cardiovascular hemodynamics or conduction, apart from a modest increase in corrected QT interval (but no torsades de pointes). Importantly, the efficacy and tolerability of ranolazine ER were not affected by old age and co-morbid conditions (heart failure or diabetes mellitus).

Comparative trials of ranolazine ER with other antianginal agents and trials examining its effects on long-term morbidity and mortality in patients with ischemic heart disease are required to determine with greater certainty the place of the drug in current antianginal therapy. Nevertheless, ranolazine ER may well prove to be a useful alternative and adjunct to conventional hemodynamic antianginal therapy in the treatment of chronic stable angina.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110(8): 904–10

    Article  PubMed  CAS  Google Scholar 

  2. Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J 2004; 6 (Suppl. I): 13–7

    Article  Google Scholar 

  3. Brown CM, Clarke B, Dye A, et al. Pharmacological profile of ranolazine, a metabolic modulator active in ischemia [abstract]. Br J Pharmacol 1988; 93 Suppl.: 248P

    Article  Google Scholar 

  4. Rousseau MF, Pouleur H, Cocco G, et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005 Feb 1; 95 (3): 311–6.

    Article  PubMed  CAS  Google Scholar 

  5. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents: Ranolazine Study Group. Am J Cardiol 1999 Jul 1; 84 (1): 46–50.

    Article  PubMed  CAS  Google Scholar 

  6. Thadani U, Ezekowitz M, Fenney L, et al. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris: Ranolazine Study Group. Circulation 1994 Aug; 90 (2): 726–34.

    Article  PubMed  CAS  Google Scholar 

  7. Song Y, Shryock JC, Wu L, et al. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovascul Pharmacol 2004; 44(2): 192–9

    Article  CAS  Google Scholar 

  8. Wu L, Song Y, Shryock JC, et al. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther 2004; 310(2): 599–605

    Article  PubMed  CAS  Google Scholar 

  9. CV Therapeutics Inc. Product information (US): Ranexa™ (ranolazine) extendedrelease tablets 500mg; Jan 2006 [online]. Available from URL: http://ranex-a.com/Ranexa.pdf [Accessed 2006 Feb 22]

  10. Wolff AA. MARISA: monotherapy assessment of ranolazine in stable angina [abstract no. 1196–101]. J Am Coll Cardiol 2000 Feb; 35 (Suppl. A): 408. Plus poster presented at the 49th Annual Scientific Session of the American College of Cardiology; 2000 Mar 12–15; Anaheim (CA)

    Google Scholar 

  11. Abdallah H, Jerling M. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets. J Clin Pharmacol 2005 Jul; 45 (7): 802–9.

    Article  PubMed  CAS  Google Scholar 

  12. Chu N, Sohoo D, Sun H-L, et al. In vitro metabolism of ranolazine [abstract no. 363]. Drug Metab Rev 2003; 35 Suppl. 2: 182

    Google Scholar 

  13. Jerling M, Abdallah H. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther 2005 Sep; 78 (3): 288–97.

    Article  PubMed  CAS  Google Scholar 

  14. Jerling M, Huan BL, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol 2005 Apr; 45 (4): 422–33.

    Article  PubMed  CAS  Google Scholar 

  15. Chaitman BR. Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise peformance with ranolazine, a pFOX inhibitor. Curr Probl Cardiol 2002 Dec; 27 (12): 527–55.

    Article  PubMed  Google Scholar 

  16. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004 Apr 21; 43 (8): 1375–82.

    Article  PubMed  CAS  Google Scholar 

  17. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004 Jan 21; 291 (3): 309–16.

    Article  PubMed  CAS  Google Scholar 

  18. Stone PH, Gratsianski NA, Blokhin A, et al. Anti-anginal efficacy of ranolazine when added to maximal therapy with conventional therapy: the Efficacy of Ranolazine In Chronic Angina trial [abstract no. 3491]. Circulation 2005; 112 (Suppl. 17): 748–9. Plus poster presented at the 78th annual scientific sessions of the American Heart Association; 2005 Nov 13–16; Dallas (TX)

    Google Scholar 

  19. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27(1): 42–8

    Article  PubMed  CAS  Google Scholar 

  20. White HD, Skettino S, Chaitman BR, et al. Anti-anginal efficacy of ranolazine addition to beta blocker or calcium antagonist therapy in patients with a history of heart failure [abstract no. 1746]. Circulation 2002 Nov 5; 106 (19 Suppl. II): 349–50

    Google Scholar 

  21. Chaitman BR, Skettino S, Parker JO, et al. Efficacy of ranolazine as add-on therapy for chronic angina in elderly patients [abstract no. 1649]. Circulation 2002 Nov 5; 106 (19 Suppl. II): 330

    Google Scholar 

  22. Koren MJ, Crager M, Sweeney M. Ranolazine safety and tolerability during long term treatment of stable angina [abstract no. 999–253]. J Am Coll Cardiol 2006; 47 (Suppl. 1): 218A

    Google Scholar 

Download references

Acknowledgments

The full text article in Drugs 2006; 66 (5): 693-710 was reviewed by B.R. Chaitman, Division of Cardiology, Saint Louis University Health Sciences Center, St Louis, Missouri, USA; G. Cocco, University of Ferrara, Ferrara, Italy; G.D. Lopaschuk, Cardiovascular Research Group, Heritage Medical Research Centre, University of Alberta, Edmonton, Alberta, Canada; P.A. McCullough, Divisions of Cardiology, Nutrition, and Preventive Medicine, Department of Medicine, William Beaumont Hospital, Royal Oak, Michigan, USA; J.O. Parker, Department of Medicine, Kingston General Hospital, Kingston, Ontario, Canada; C.J. Pepine, Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida, USA; H. Taegtmeyer, Division of Cardiology, Department of Internal Medicine, University of Texas Health Science Center, Houston, Texas, USA.

Author information

Authors and Affiliations

  1. Wolters Kluwer Health, Adis, Auckland, New Zealand

    M. Asif A. Siddiqui & Susan J. Keam

  2. an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    M. Asif A. Siddiqui & Susan J. Keam

Authors
  1. M. Asif A. Siddiqui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Asif A. Siddiqui.

Additional information

This Spotlight is derived from abstract and summary text of an Adis Drug Evaluation originally published in full in Drugs 2006; 66 (5): 693–710.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siddiqui, M.A.A., Keam, S.J. Spotlight on Ranolazine in Chronic Stable Angina Pectoris. Am J Cardiovasc Drugs 6, 357–359 (2006). https://doi.org/10.2165/00129784-200606050-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200606050-00009

Keywords

Search

Navigation